No Detail Found!

Safety and Efficacy of Low Molecular Weight Heparin Vs. Direct Oral Anticoagulants in Cancer-Associated Venous Thromboembolism

Author(s)
Samar Minallah Department of Internal Medicine, Shaukat Khanum Memorial Cancer Hospital,Peshawar,Pakistan
Amer Rehman Farooqi Department of Internal Medicine, Shaukat Khanum Memorial Cancer Hospital,Peshawar,Pakistan
Kashif Sajjad Department of Internal Medicine, Shaukat Khanum Memorial Cancer Hospital,Peshawar,Pakistan
Zainab Shakeel Department of Internal Medicine, Shaukat Khanum Memorial Cancer Hospital,Peshawar,Pakistan
Manzoor Khan Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital,Peshawar,Pakistan
Sajjad Ullah Department of Pharmacy, Shaukat Khanum Memorial Cancer Hospital,Peshawar,Pakistan
Abstract
To compare the safety and e cacy of low molecular weight heparin (LMWH) and direct oral anticoagulants (DOACs) in treating venous thromboembolism (VTE) among cancer patients. Study Design: Descriptive study. Place and Duration of the Study:Department of General Medicine, Shaukat Khanum Memorial Cancer Hospital, Peshawar, Pakistan, from February to September 2023. Methodology: This retrospective study included 150 cancer patients treated with either LMWH or DOACs for at least one month. The safety and e cacy were measured in terms of occurrences of major bleeding (assessed through International Society of Thrombosis and Haemostasis (ISTH) score) and recurrent VTE within six months. Results: Among the 150 patients studied, 99 (66%) received LMWH, while 51 (34%) were treated with DOACs. The mean age in the LMWH group was 45.49 ± 13.48 years, compared to 54.00 ± 12.22 years in the DOAC group. Major bleeding events were more frequent 11 (11.1%) in the LMWH group than 3 (5.9%) in the DOAC group, though this di erence was not statistically signi cant (p = 0.383). Recurrence rates of VTE were higher 8 (16%) in the DOAC group compared to the LMWH group 10 (10.1%), with no statistically signi cant di erence (p = 0.300). The LMWH therapy was associated with a longer median treatment duration (170 daysversus 166.5 days for DOACs; p = 0.290) and a statistically signi cant shorter hospital stay (0-25 dvaeyrssus 0-30 days for LMWH; p = 0.038). Conclusion: Both DOACs and LMWH are equally e ective for managing VTE. DOACs o er relatively shorter treatment durations and hospital stays, though they have a slightly higher recurrence rate and comparable or lower major bleeding risk.
Publication Details
Page(s) 875-880
Published Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 07, Year: 2025

Request the full text from PASTIC

Keywords
Thrombosis, venous thromboembolism, low molecular weight heparin, Cancer, Direct Oral Anticoagulants
References
Donnellan E,Khorana AA .2017 .Cancer and venous thromboembolic disease: A review. Oncologist, 0214(2) : 199-207.
Mulder FI,Horvath-Puho E,van Es N,Laarhoven HWM,Pedersen L,Moik F .2020 .Venous thromboembolism in cancer patients: A population-based cohort study. Blood, 10(14) : 1959-69.
Lanting VR,Takada T,Bosch FT,Marshall A,Grosso MA,Young AM .2018 .Risk of recurrent venous thrombo-embolism in patients with cancer: An individual patient data metaanalysis and development of a prediction model. Thromb Haemost, 78(6) : 589-96.
Bertoletti L,Girard P,Elias A,Espitia O,Schmidt J,Couturaud F .2023 .Recurrent venous thromboembolism in anticoagulated cancer patients: Diagnosis and treatment. Arch Cardiovasc Dis, 11(1) : 84-93.
McBane II RD,Vlazny DT,Houghton D,Casanegra AI,Froehling D,Daniels P .2023 .Survival implications of thrombus recurrence or bleeding in cancer patients receiving anticoagulation for venous thromboembolism treatment. Thromb Haemost, 10(5) : 535-44.
Araji G,Wei C,Chowdhry V,Wu K,Khamis Z,Sarkis T .2024 .Cancer-associated venous thromboembolism among solid and haematological malignancies: A comprehensive national study. Blood, 10(1) : 2641.
Sheth RA,Niekamp A,Quencer KB,Shamoun F,Knuttinen MG,Naidu S .2017 .7(Suppl 3): S178. Cardiovasc Diagn Ther, 11 : .
Ay C,Pabinger I,Cohen AT .2017 .Cancer-associated venous thromboembolism: Burden, mechanisms, and manage-ment. Thromb Haemost, 10(2) : 219-30.
Uno H,Xiong H,Cronin C,Schrag D,Connors JM .2024 .Predictors of recurrent venous thromboembolism and major bleeding in patients with cancer: A secondary analysis of the CANVAS trial. Thromb Res, 109184 : 109184.
Moik F,Englisch C,Pabinger I,Ay C .2021 .Risk assessment models of cancer-associated thrombosis potentials and perspectives. Thromb Update, 100075 : 100075.
Yhim HY .2022 .Challenging issues in the management of cancerassociated venous thromboembolism. Blood Res, 2022025(S1) : 44-8.
Key NS,Khorana AA,Kuderer NM,Bohlke K,Lee AY,Arcelus JI .2023 .Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline updateJ. Clin Oncol, 10(16) : 3063-71.
Pritchard ER,Murillo JR,Putney D,Hobaugh EC .2019 .Singlecenter, retrospective evaluation of safety and e cacy of direct oral anticoagulantsversus low-molecular-weight heparin and vitamin K antagonist in patients with cancer. J Oncol Pharm Pract, 10(1) : 52-9.
Xiang E,Ahuja T,Raco V,Cirrone F,Green D,Papadopoulos J .2018 .Anticoagulation prescribing patterns in patients with cancer. J Thromb Thrombolysis, 10(1) : 89-98.
Fovel LM,Seabury RW,Miller CD,Darko W,Probst LA,Horvath L .2021 .Safety and e cacy of direct oral anticoagulant therapy in patients with cancer. J Pharm Pract, 10(5) : 710-4.
Alsubaie NS,Al Rammah SM,Alshouimi RA,Alzahrani MY,Al Yami MS,Almutairi AR .2021 .The use of direct oral anticoagulants for thromboprophylaxis or treatment of cancer-associated venous thromboembolism: A meta-analysis and review of the guidelines. Thromb J, 10(1) : 76.
Zhou H,Ye LL,Zhou JT,Ma FX,Ma JJ,Zhang JH .2024 .Direct oral anticoagulants (DOACs) versus low-molecular-weight heparin (LMWH) for extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis. Surg Endosc, 10(3) : 1131-8.
Adrian SG,Perez CI,Carmona-Bayonas A,Moran LO,Perez JR,Del Prado PM .2024 .Cancer-related thrombosis: Impact of biological sex on the risk of rethrombosis and bleeding. Haematologica, 286152 : .
Joyce E,Haymart B,Kong X,Ali MA,Carrigan M,Kaatz S .2022 .Length of anticoagulation in provoked venous thromboembolism: A multicenter study of how real-world practice mirrors guideline recommendations. J Am Heart Assoc, 10(21) : .
Alexander P,Visagan S,Issa R,Gorantla VR,Thomas SE .2021 .Current trends in the duration of anticoagulant therapy for venous thromboembolism: A systematic review. Cureus, 10(10) : .
0

Citations

0

Downloads

25

Views